AstraZeneca and Merck's Lynparza set to 'dominate' PARP market as it looks to grow cancer offerings with 100-plus ...
AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. That’s according to a new report out by analysts at GlobalData, …